CXCR4WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplantMYD88L265P-directed survival signalling in Waldenström macroglobulinaemia cells-Reference-Cited by-同舟云学术

CXCR4WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplantMYD88L265P-directed survival signalling in Waldenström macroglobulinaemia cells

Published:2014-11-05 Issue:5 Volume:168 Page:701-707
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Cao Yang¹²,Hunter Zachary R.¹³,Liu Xia¹²,Xu Lian¹,Yang Guang¹²,Chen Jie¹,Tsakmaklis Nickolas¹,Kanan Sandra¹,Castillo Jorge J.¹²^ORCID,Treon Steven P.¹²

Affiliation:

1. Bing Center for Waldenstrom's Macroglobulinemia; Dana Farber Cancer Institute; Boston MA USA

2. Department of Medicine; Harvard Medical School; Boston MA USA

3. Department of Pathology; Boston University Medical School; Boston MA USA

Funder

Leukemia and Lymphoma Society

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13200/fullpdf

Reference20 articles.

1. Activation of TAK1 by MYD88 L265P drives malignant B-cell growth in non-Hodgkin lymphoma;Ansell;Blood Cancer Journal,2014

2. Regulation of CXCR4 signaling;Busillo;Biochimica Biophysica Acta,2007

3. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling;Busillo;Journal of Biological Chemistry,2010

4. The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia;Cao;Leukemia,2014

5. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome;Dotta;Current Molecular Medicine,2011

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk stratification, and clinical problems.;Mediterranean Journal of Hematology and Infectious Diseases;2024-06-29

2. Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia;Blood Advances;2024-04-27

3. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia;Blood;2024-04-25

4. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia;Blood Advances;2024-03-28

5. Waldenstrom Macroglobulinemia;Comprehensive Hematology and Stem Cell Research;2024